Ventaira Pharmaceuticals Overview
- Year Founded
-
1997
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Ventaira Pharmaceuticals General Information
Description
Developer of pharmaceutical products for inhalation. The company develops inhaled drugs including fentanyl for the treatment of breakthrough pain and salmeterol for asthma. It focuses on the development of new inhalation products by utilizing its novel proprietary electrohydrodynamic aerosolization.
Contact Information
Website
www.ventaira.comCorporate Office
- 1801 Watermark Drive
- Suite 100
- Columbus, OH 43215
- United States
Corporate Office
- 1801 Watermark Drive
- Suite 100
- Columbus, OH 43215
- United States
Ventaira Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 30-Oct-2007 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 12-Jun-2007 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series C) | 19-Oct-2005 | $13.5M | $38.5M | Completed | Generating Revenue | |
| 1. Later Stage VC (Series B) | 27-Feb-2003 | $25M | $25M | Completed | Generating Revenue |
Ventaira Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B | ||||||||
| Class 2 Series A | ||||||||
| Class 1 Series A | 302,956 | $0.010000 | 8% | $1.74 | $1.74 | $1.74 | 0.89% | |
| Series A | 685,803 | $0.010000 | 8% | $1.74 | $1.74 | $1.74 | 2.01% |
Ventaira Pharmaceuticals Patents
Ventaira Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-118323-S | Drug dispenser | Inactive | 24-May-2006 | ||
| WO-2007094833-A1 | Accurate metering system | Inactive | 14-Feb-2006 | ||
| WO-2007094835-A1 | Dissociated discharge ehd sprayer with electric field shield | Inactive | 14-Feb-2006 | ||
| WO-2007011866-A2 | Improved dispensing device and method | Inactive | 15-Jul-2005 | ||
| WO-2007011866-A3 | Improved dispensing device and method | Inactive | 15-Jul-2005 | A61M15/02 |
Ventaira Pharmaceuticals Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Battelle Ventures | Venture Capital | Minority | ||
| Early Stage Partners | Venture Capital | Minority | ||
| Fletcher Spaght Ventures | Venture Capital | Minority | ||
| James Richardson and Sons | Merchant Banking Firm | Minority | ||
| Merlin BioMed Group | Venture Capital | Minority |
Ventaira Pharmaceuticals FAQs
-
When was Ventaira Pharmaceuticals founded?
Ventaira Pharmaceuticals was founded in 1997.
-
Where is Ventaira Pharmaceuticals headquartered?
Ventaira Pharmaceuticals is headquartered in Columbus, OH.
-
What industry is Ventaira Pharmaceuticals in?
Ventaira Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Ventaira Pharmaceuticals a private or public company?
Ventaira Pharmaceuticals is a Private company.
-
What is Ventaira Pharmaceuticals’s current revenue?
The current revenue for Ventaira Pharmaceuticals is .
-
How much funding has Ventaira Pharmaceuticals raised over time?
Ventaira Pharmaceuticals has raised $39.5M.
-
Who are Ventaira Pharmaceuticals’s investors?
Battelle Ventures, Early Stage Partners, Fletcher Spaght Ventures, James Richardson and Sons, and Merlin BioMed Group are 5 of 11 investors who have invested in Ventaira Pharmaceuticals.
-
When was Ventaira Pharmaceuticals acquired?
Ventaira Pharmaceuticals was acquired on 30-Oct-2007.
-
Who acquired Ventaira Pharmaceuticals?
Ventaira Pharmaceuticals was acquired by Battelle.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process